The One ETF Really Benefiting From the Intercept Pharma News

No need to do a double take with the following because it is true: Shares of Intercept Pharmaceuticals (NasdaqGM: ICPT) are up $210, or a tidy 290%, after trials for the company’s liver disease treatment proved successful. That is good news for the biotechnology sector, which is coming off another...